Safety and Effectiveness Evaluation of a Public Smoking Cessation Policy

Project number: 
15-132
Approval date: 
Monday, September 28, 2015
Principal Investigator: 
Carney,Greg
Institution: 
University of British Columbia (UBC)
Funding Agency: 
Not Available
Datasets requested: 
PharmaNet
Medical Services Plan (BC Ministry of Health)
Consolidation registry (Ministry of Health)
Hospital Separations (BC Ministry of Health)
Consolidation - demographic (Ministry of Health)
Deaths (BC Vital Statistics Agency)
MSP Registration & Premium Billing(BC Ministry of Health)
Research objective: 

Project Objectives:
This is an evaluation of the BC Ministry of Healths smoking cessation policy. The evaluation will consist of 4 analyses:

1. What is the comparative effectiveness of Champix, Zyban, Thrive, and Habitrol therapy for smoking cessation in a population based publicly funded reimbursement program?

Hypothesis: No difference in smoking cessation effectiveness.

2. What is the comparative safety of Champix, Zyban, Thrive, and Habitrol therapy for smoking cessation in a population based publicly funded reimbursement program.

Hypothesis: No difference in safety, in terms of mortality, suicidality, and total emergency hospital admissions.

3. How do the direct system health costs compare between smoking cessation products offered under BC's population based tobacco treatment program.

Hypothesis: Any difference in cost is comparable to the difference cost for each product.

4. What effect did the Smoking Cessation Program have on utilization rates of use of the four smoking cessation products?

Hypothesis: The Smoking Cessation Program increased the utilization of smoking cessation products.


Page last revised: December 5, 2017